Probe primer set for detecting mutations in myeloid leukemia genes by high-throughput sequencing and its application

The probe primer set for high-throughput sequencing addresses the limitations of existing methods by enabling simultaneous detection of multiple myeloid leukemia gene mutations with high specificity and efficiency, reducing costs and experimental time.

JP7591097B2Active Publication Date: 2024-11-27AMOY DIAGNOSTICS CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023098553
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-06-28
Filing Date
2023-06-15
Publication Date
2024-11-27
Estimated Expiration
2043-06-15

AI Technical Summary

Technical Problem

Current leukemia detection methods, such as FISH, qPCR, Sanger, and NGS, face limitations in detecting various types of mutations in myeloid leukemia genes, including FLT3-ITD, due to technical barriers like poor specificity, high costs, and complexity, especially in high-throughput sequencing.

Method used

A probe primer set comprising DNA and RNA probes, along with RNA reverse transcription primers, designed for high-throughput sequencing, capable of simultaneously detecting SNVs, InDels, and fusions in multiple myeloid leukemia genes, utilizing specific modifications like phosphorylation and thiolation to enhance specificity and uniformity.

Benefits of technology

The probe primer set enables efficient, cost-effective, and high-specificity detection of 10 to 53 myeloid leukemia genes in a single sample, reducing experimental costs and time, with high concordance rates for SNVs, InDels, and fusions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591097000044
    Figure 0007591097000044
  • Figure 0007591097000045
    Figure 0007591097000045
  • Figure 0007591097000046
    Figure 0007591097000046
Patent Text Reader

Abstract

To provide probe primer sets for detecting mutation in myelogenous leukemia genes by high throughput sequencing.SOLUTION: The invention discloses a probe primer set for detecting mutation in myelogenous leukemia genes by high throughput sequencing, where the probe primer set comprises a DNA probe set, an RNA probe set and an RNA reverse transcription primer set.EFFECT: According to the invention, SNV, InDel and Fusion of 10 to 53 genes in a single sample can be simultaneously detected in a single tube; the detection performance is good, the specificity is higher than that of the existing capture method technology, and the probe homogeneity is higher than that of the multiplex PCR technology; the price is lower, the operability is higher, DNA and RNA share a detection system in one tube, the experiment cost is reduced, and the experiment steps are shortened.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the technical field of molecular biology, and in particular to a probe primer set for detecting mutations in myeloid leukemia genes by high-throughput sequencing and its application. [Background technology]

[0002] Leukemia is a malignant Crohn's disease that originates from hematopoietic stem cells, in which damaged cells (leukemia cells) develop proliferation control, differentiation disorders, and apoptosis disorders, accumulating in large quantities in bone marrow and other hematopoietic tissues, inhibiting the normal hematopoietic function of the bone marrow, and infiltrating tissues and organs such as lymph nodes, liver, and spleen. Depending on the degree of differentiation and maturation of leukemia cells and the natural course, leukemia is classified into two types: acute (AL) and chronic (CL).

[0003] AL is classified into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) depending on the cell lineage that is primarily affected. CL is classified into chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), and rarer types of leukemia such as hairy cell leukemia and prolymphocytic leukemia.

[0004] The incidence rate of leukemia in Japan is (3-4) / 100,000. In terms of death rates from malignant tumors, leukemia ranks 6th (male) and 7th (female), and 1st in children and adults under 35 years of age. AL is more common than CL (approximately 5.5:1), of which acute myeloid leukemia is the most common (1.62 / 100,000), followed by acute lymphocytic leukemia (0.69 / 100,000) and CML (0.39 / 100,000), with CL being rare (0.05 / 100,000). The incidence rate in men was slightly higher than that in women (1.81:1). Acute myeloid leukemia is the most common type of acute leukemia in adults, and acute lymphocytic leukemia is the most common type in children. The incidence rate of chronic myeloid leukemia gradually increases with age. Chronic lymphocytic leukemia occurs significantly after the age of 50.

[0005] Currently, the leukemia-related gene detection products on the market are mainly based on FISH, qPCR, Sanger and NGS technologies. The target genes related to leukemia drugs include FLT3, IDH1, IDH2, etc., among which, FLT3-ITD (internal tandem duplication) has many types of mutations and the location is not fixed, so it cannot be completely found by Sanger method. In addition, mutations in leukemia include point mutations (SNV) of multiple genes, deletion mutations (InDel), fusion mutations (Fusion), and qPCR is a severe technical barrier to the detection of multiple genes, but the mutation types of FISH detection are few and cannot meet all clinical requirements. The reason why there are few NGS platform products based on capture method and multiplex PCR technology is that the capture method has the problems of complicated operation and high cost, while the multiplex PCR technology has the problems of poor specificity and uniformity, which wastes data. Summary of the Invention [Problem to be solved by the invention]

[0006] The present invention aims to overcome the drawbacks of the prior art and to provide a probe primer set for detecting mutations in myeloid leukemia genes by high-throughput sequencing.

[0007] Another object of the present invention is to provide a kit for detecting myeloid leukemia gene mutations using a high-throughput sequencing method.

[0008] A further object of the present invention is to provide an application of the following probe primer set in the manufacture of a myeloid leukemia gene mutation detection kit by high-throughput sequencing. [Means for solving the problem]

[0009] A probe primer set for detecting mutations in myeloid leukemia genes by high-throughput sequencing, comprising: The DNA probe set includes an RNA probe set and an RNA reverse transcription primer set, among which: The DNA probe set includes sequences shown in SEQ ID NOs. 0059 to 0066, 0102 to 0131, 0158 to 0172, 0244 to 0280, 0285 to 0293, 0520 to 0625, and 0821 to 0836, and all of the sequences of the DNA probe set are phosphorylated; The RNA probe sets were SEQ ID NO.1077, SEQ ID NO.1082-1168, SEQ ID NO.1170-1171, SEQ ID NO.1174, SEQ ID NO.1176, SEQ ID NO.1184-1186, SEQ ID NO.1188-1198, SEQ ID NO.1201, SEQ ID NO.1203-1221, SEQ ID NO.1234-1238, SEQ ID NO.1249-1252, SEQ ID NO.1266, SEQ ID NO.1271-1357, SEQ ID NO.1359-1360, SEQ ID NO.1363, SEQ ID NO.1365, SEQ ID NO.1373-1375, SEQ ID NO.1377-1387, SEQ ID NO.1389-1390, SEQ ID NO.1391-1392, SEQ ID NO.1393-1394, SEQ ID NO.1395-1396, SEQ ID NO.1397-1398, SEQ ID NO.1398-1400, SEQ ID NO.1399-1410, SEQ ID NO.1420-1422, SEQ ID NO.1421-1424, SEQ ID NO.1422-1426, SEQ ID NO.1423-1428, SEQ ID NO.1424-1429, SEQ ID NO.1430-1432, SEQ ID NO.1431-1434, SEQ ID NO.1432-1436, SEQ ID NO.1433-1436, SEQ ID NO.1434-1438, SEQ ID NO.1435-1439, S SEQ ID NO.1390, SEQ ID NO.1392 to 1410, SEQ ID NO.1423 to 1427 and SEQ ID NO.1438 to 1441, and in the sequences shown in SEQ ID NO.1077, SEQ ID NO.1082 to 1168, SEQ ID NO.1170 to 1171, SEQ ID NO.1174, SEQ ID NO.1176, SEQ ID NO.1184 to 1186, SEQ ID NO.1188 to 1198, SEQ ID NO.1201, SEQ ID NO.1203 to 1221, SEQ ID NO.1234 to 1238 and SEQ ID NO.1249 to 1252, all of the six nucleotides from the 5' end are modified by thiolation, and in the sequences shown in SEQ ID NO.1266, SEQ ID NO.1271 to 1357, SEQ ID NO.1278 to 1359, SEQ ID NO.1280 to 1360, SEQ ID NO.1282 to 1361, SEQ ID NO.1283 to 1362, SEQ ID NO.1284 to 1363, SEQ ID NO.1285 to 1364, SEQ ID NO.1286 to 1365, SEQ ID NO.1287 to 1366, SEQ ID NO.1289 to 1370, SEQ ID NO.1390, SEQ ID NO.1392 to 1410, SEQ ID NO.1423 to 1427 and SEQ ID NO.1438 to 1441, The sequences shown in SEQ ID NOs. 1359 to 1360, 1363, 1365, 1373 to 1375, 1377 to 1387, 1390, 1392 to 1410, 1423 to 1427 and 1438 to 1441 are all phosphorylated and all six nucleotides from the 3' end are modified by thiolation, The RNA reverse transcription primer set includes sequences shown in SEQ ID NO.1455, SEQ ID NO.1460-1546, SEQ ID NO.1548-1549, SEQ ID NO.1552, SEQ ID NO.1554, SEQ ID NO.1562-1564, SEQ ID NO.1566-1576, SEQ ID NO.1579, SEQ ID NO.1581-1599, SEQ ID NO.1612-1616 and SEQ ID NO.1627-1630.

[0010] In a preferred embodiment of the present invention, the DNA probe set comprises sequences shown in SEQ ID NOs.0001-0008, SEQ ID NOs.0059-0082, SEQ ID NOs.0102-0131, SEQ ID NOs.0158-0172, SEQ ID NOs.0184-0280, SEQ ID NOs.0285-0293, SEQ ID NOs.0296-0302, SEQ ID NOs.0346-0351, SEQ ID NOs.0355-0459, SEQ ID NOs.0520-0640, SEQ ID NOs.0692-0836, SEQ ID NOs.0850-1001 and SEQ ID NOs.1026-1074, and all of the sequences of the DNA probe set are phosphorylated; The RNA probe set includes sequences shown in SEQ ID NOs. 1075 to 1252 and 1264 to 1441, in which all six nucleotides from the 5' end of the sequence shown in SEQ ID NOs. 1075 to 1252 are modified by thiol, all sequences shown in SEQ ID NOs. 1264 to 1441 are phosphorylated, and all six nucleotides from the 3' end of the sequence shown in SEQ ID NOs. 1264 to 1441 are modified by thiol, The RNA reverse transcription primer set includes the sequences shown in SEQ ID NOs. 1453-1630.

[0011] Preferably, the DNA probe set comprises sequences shown in SEQ ID NOs. 0001 to 1074, and all of the sequences shown in SEQ ID NOs. 0001 to 1074 are phosphorylated; The RNA probe set includes the sequences shown in SEQ ID NOs. 1075 to 1452, in which all six nucleotides from the 5' end are modified by thiol, the sequences shown in SEQ ID NOs. 1264 to 1452 are all phosphorylated, and all six nucleotides from the 3' end are modified by thiol, The RNA reverse transcription primer set includes the sequences shown in SEQ ID NOs. 1453-1641.

[0012] More preferably, the probe primer set comprises the DNA probe set, an RNA probe set and an RNA reverse transcription primer set.

[0013] More preferably, the DNA probe set consists of the sequences shown in SEQ ID NOs. 0001-1074.

[0014] More preferably, the RNA probe set consists of the sequences shown in SEQ ID NOs. 1075-1452.

[0015] More preferably, the RNA reverse transcription primer set consists of the sequences shown in SEQ ID NOs. 1453-1641.

[0016] More preferably, the DNA probe set consists of the sequences shown in SEQ ID NOs. 0001 to 1074, the RNA probe set consists of the sequences shown in SEQ ID NOs. 1075 to 1452, and the RNA reverse transcription primer set consists of the sequences shown in SEQ ID NOs. 1453 to 1641.

[0017] A kit for detecting a myeloid leukemia gene mutation comprises the above-mentioned probe primer set.

[0018] The application of said probe primer set in the manufacture of a myeloid leukemia gene mutation detection kit by high-throughput sequencing. Effect of the Invention

[0019] 1. The present invention provides FLT3, TP53, RUNX1, CEBPA, DNMT3A, NPM1, TET2, WT1, NRAS, ASXL1, IDH2, KMT2A, KIT, KRAS, IDH1, PHF6, PTPN11, STAG2 , NF1, U2AF1, BCOR, CBL, GATA2, SRSF2, NUP98, MLLT10, CREBBP, CBFB, ABL1, ETV6, NUP214, PML, ZRSR2, SF3B1, EZH2, CALR, RIT1 Based on the mutation types associated with IKZF1, RB1, MYC, BRAF, CSF3R, GATA1, JAK2, JAK3, MPL, MYD88, PDGFRA, SETBP1, CTCF, DIS3, FBXW7, and MAX, a high-throughput sequencing probe primer set for myeloid leukemia detection was designed and obtained, enabling simultaneous detection of SNVs, InDels, and Fusions in 10 to 53 genes in a single sample in a single tube.

[0020] 2. The present invention has good detection performance, higher specificity than the existing capture method, and higher probe uniformity than multiplex PCR technology.

[0021] 3. The present invention provides a cheaper, more user-friendly system for simultaneously detecting DNA and RNA in a single tube, reducing the cost of experiments and shortening the experimental process. [Brief description of the drawings]

[0022] [Figure 1] FIG. 2 is an experimental flow diagram of an embodiment of the present invention. [Diagram 2] FIG. 1 is a quality control chart of the detection library in Example 1 of the present invention. [Diagram 3] FIG. 13 shows the correlation results between the detection results of the Master Panel and the Myeloid Blood Cancer Panel in Example 2 of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0023] Hereinafter, an embodiment of the present invention will be described with reference to the drawings.

[0024] The probe primer sets in the following examples include a DNA probe set, an RNA probe set, and an RNA reverse transcription primer set, and are specifically as shown in Table 1.

[0025] The DNA probe set consists of the sequences shown in SEQ ID NOs. 0001-1074.

[0026] The RNA probe set consists of the sequences shown in SEQ ID NOs. 1075 to 1452. In the sequences shown in SEQ ID NOs. 1075 to 1263, all six nucleotides from the 5' end are modified with thiol. In the sequences shown in SEQ ID NOs. 1264 to 1452, all sequences are NEB phosphorylation sequences, and all six nucleotides from the 3' end are modified with thiol.

[0027] The RNA reverse transcription primer set consists of the sequences shown in SEQ ID NOs. 1453 to 1641. Table 1. Summary of probe sequences JPEG0007591097000001.jpg255170JPEG0007591097000002.jpg255170JPEG0007591097000003.jpg255170JPEG0007591097000004.jpg255170JPEG0007591097000005.jpg255170JPEG0007591097000006.jpg255170JPEG0007591097000007.jpg255170JPEG0007591097000008.jpg255170JPEG0007591097000009.jpg255170JPEG0007591097000010.jpg255170JPEG0007591097000011.jpg255170JPEG0007591097000012.jpg255170JPEG0007591097000013.jpg255170JPEG0007591097000014.jpg255170JPEG0007591097000015.jpg255170JPEG0007591097000016.jpg255170JPEG0007591097000017.jpg255170JPEG0007591097000018.jpg255170JPEG0007591097000019.jpg255170JPEG0007591097000020.jpg255170JPEG0007591097000021.jpg255170JPEG0007591097000022.jpg255170JPEG0007591097000023.jpg255170JPEG0007591097000024.jpg255170JPEG0007591097000025.jpg255170JPEG0007591097000026.jpg255170JPEG0007591097000027.jpg255170JPEG0007591097000028.jpg255170JPEG0007591097000029.jpg255170JPEG0007591097000030.jpg255170JPEG0007591097000031.jpg255170JPEG0007591097000032.jpg255170JPEG0007591097000033.jpg255170JPEG0007591097000034.jpg255170JPEG0007591097000035.jpg255170JPEG0007591097000036.jpg255170JPEG0007591097000037.jpg255170JPEG0007591097000038.jpg203170 or more in the sequence. r is g or a; n is a, g, c or t; h is a, c or t; v is a, g or c; b is g, c or t; d is a, g or t; y is t or c; * indicates thio modification.

[0028] In the following examples, reference is made to CN109593757A for each MBCP-labeled material. MBCP-Hybridization Buffer is 10× Ampligase Buffer. The composition of the MBCP-Extension Ligation Master Mix is ​​as follows: JPEG0007591097000039.jpg51170MBCP-Exonuclease A is Exonuclease I, MBCP-Exonuclease B is an Exonuclease III. MBCP-PCR Master Mix is ​​2× iProof HF Master Mix.

[0029] Example 1 Testing of myeloid leukemia standard samples The standard should be the best core for evaluating different detection methods and should include all mutation types that should be covered in the panel. The DNA standard was purchased from Gene Well Co., Ltd. (Chinese: Jingliang), and the validation method was ddPCR. The RNA standard was a self-made product, and the validation method was ddPCR (linear R 2The SNV and InDel frequencies were diluted to about 3%, and the fusion copy number was diluted to about 3 copies / ng. The mutation information of the standard product is shown in Table 2. Table 2 Standard product mutation information table JPEG0007591097000040.jpg50170

[0030] As shown in Figure 1, the specific process is as follows:

[0031] (1) Pre-denaturation: Pipette 200 ng of RNA and 2 μL of MBCP-RT-Primers (the amount of a single RNA reverse transcription primer used in the RNA reverse transcription primer set is 1 pmol), add water to the volume of 8.5 μL, perform PCR at 65°C, and immediately place on ice after 5 minutes.

[0032] (2) Reverse transcription: Add 1.25 μL of MBCP-RT Reaction Mix (reverse transcription buffer) and 0.25 μL of MBCP-RT Reverse Transcriptase (reverse transcriptase) to the reaction mixture so that the total reaction mixture is 10 μL. Perform PCR at 50°C for 50 minutes and 98°C for 10 minutes, and store at 4°C.

[0033] (3) Hybridization: Add 50 ng of standard sample DNA to the reaction system, then add 2 μL of MBCP-Probe (for the DNA probe set and RNA probe set, the amount of a single DNA probe used is 0.004 pmol, and the amount of a single RNA probe used is 0.02 pmol) and 1 μL of MBCP-Hybridization Buffer, and add water to make up to 20 μL. Perform PCR at 98°C for 5 minutes, 60°C for 2 hours, and store at 4°C.

[0034] (4) Extension and ligation: Add 1 μL of MBCP-Extension Ligation Master Mix to the reaction system to make the total system 21 μL, perform PCR at 60° C. for 10 minutes, and store at 4° C.

[0035] (5) Enzyme cleavage: 0.5 μL of MBCP-Exonuclease A and 0.5 μL of MBCP-Exonuclease B are added to the reaction system so that the total volume becomes 22 μL. PCR is carried out at 37° C. for 30 minutes and at 95° C. for 10 minutes, and then stored at 4° C.

[0036] (6) PCR amplification: 1.5 μL of MBCP-N7 Primer, 1.5 μL of MBCP-S5 Primer, and 25 μL of MBCP-PCR Master Mix are added to the reaction system so that the total system becomes 50 μL. PCR is performed at 98°C for 1 minute (98°C, 20 minutes, 61°C, 30 minutes, 72°C, 20 minutes, 25 cycles), and then at 72°C for 5 minutes, and then stored at 4°C.

[0037] (7) Purification: Add 40μL of AMPure XP beads (equilibrated at room temperature for 30 minutes) to the PCR product, mix thoroughly, leave at room temperature for 5 minutes, place on a magnetic rack, leave for 3-5 minutes, completely clarify the solution, discard the supernatant, add 200μL of 80% ethanol, wash for 30 seconds, aspirate and discard the ethanol, add 200μL of 80% ethanol again, wash for 30 seconds, aspirate and discard the ethanol, centrifuge at low speed, aspirate and discard the remaining ethanol, leave at room temperature for 3-5 minutes to dry, add 30μL of TE-low solution (pH8.0), mix thoroughly, leave at room temperature for 5 minutes, place on a magnetic rack, leave for 3-5 minutes, completely clarify the solution, collect the supernatant, and the experimental process is shown in Figure 1.

[0038] (8) Library quality control and sequencing: After the distribution of 2100 quality control library fragments, they were sequenced using an Illumina high-throughput sequencer, and the sequencing readout was 2 × 150 bp (see Figure 2 for the quality control results).

[0039] (9) Data quality control: The amount of raw data of the sample must be 2G or more, the Q30 must be 75% or more, the average effective depth must be 500× or more, the coverage must be 98% or more, and the uniformity must be 90% or more.

[0040] (10) Data analysis: The detection data was analyzed using the Xiamen AMOYDX Myeloid Leukemia Gene Mutation Detection Data Analysis System (ADXHS-AML), and the following genes were identified: FLT3, TP53, RUNX1, CEBPA, DNMT3A, NPM1, TET2, WT1, NRAS, ASXL1, IDH2, KMT2A, KIT, KRAS, IDH1, PHF6, PTPN11, STAG2, NF1, U2AF1, BCOR, CBL, GATA2, SRSF 2. Outputs information on single nucleotide mutations, insertion / deletion mutations, and fusion genes of NUP98, MLLT10, CREBBP, CBFB, ABL1, ETV6, NUP214, PML, ZRSR2, SF3B1, EZH2, CALR, RIT1, IKZF1, RB1, MYC, BRAF, CSF3R, GATA, JAK2, JAK3, MPL, MYD88, PDGFRA, SETBP1, CTCF, DIS3, FBXW7, and MAX.

[0041] Conclusion: In this example, the mutation frequency was about 3%, and low fusion mutations of 600 copies of 200 ng RNA could be stably detected (see Table 3 below). Table 3. Summary of standard product detection JPEG0007591097000041.jpg43170

[0042] Example 2. Myeloid leukemia clinical sample testing To illustrate the accuracy of the present invention in detecting mutations in clinical samples, 37 clinical samples detected by liquid-phase capture technology were selected and the concordance of detecting the same samples by different methods was examined.

[0043] As shown in Figure 1, the specific process is as follows:

[0044] (1) Pre-denaturation: Aspirate 200 ng of RNA and 2 μL of MBCP-RT-Primers with a pipette, refill with water to 8.5 μL, and perform PCR at 65°C for 5 min. Then immediately place on ice.

[0045] (2) Reverse transcription: Add 1.25 μL of MBCP-RT Reaction Mix and 0.25 μL of MBCP-RT Reverse Transcriptase to the reaction mixture to make the total reaction mixture 10 μL. Perform PCR at 50°C for 50 minutes and at 98°C for 10 minutes, and store at 4°C.

[0046] (3) Hybridization: Add 50 ng of standard sample DNA to the reaction system, then add 2 μL of MBCP-Probe and 1 μL of MBCP-Hybridization Buffer, and add water to make up to 20 μL. Perform PCR at 98°C for 5 minutes and at 60°C for 2 hours, and store at 4°C.

[0047] (4) Extension and ligation: Add 1 μL of MBCP-Extension Ligation Master Mix to the reaction system to make the total system 21 μL, perform PCR at 60° C. for 10 minutes, and store at 4° C.

[0048] (5) Enzyme cleavage: 0.5 μL of MBCP-Exonuclease A and 0.5 μL of MBCP-Exonuclease B are added to the above reaction system so that the total system becomes 22 μL. PCR is carried out at 37° C. for 30 minutes and at 95° C. for 10 minutes, and then stored at 4° C.

[0049] (6) PCR amplification: 1.5 μL of MBCP-N7 Primer, 1.5 μL of MBCP-S5 Primer, and 25 μL of MBCP-PCR Master Mix are added to the reaction system so that the total system becomes 50 μL. PCR is performed at 98°C for 1 minute (98°C, 20 seconds, 61°C, 30 minutes, 72°C, 20 minutes, 25 cycles), and then at 72°C for 5 minutes, and then stored at 4°C.

[0050] (7) Purification: Add 40 μL of AMPure XP beads (equilibrated at room temperature for 30 minutes) to 40 μL of the PCR product, mix well, leave at room temperature for 5 minutes, place on a magnetic rack, leave for 3 to 5 minutes, completely clarify the solution, discard the supernatant, add 200 μL of 80% ethanol and wash for 30 seconds, aspirate and discard the ethanol, add 200 μL of 80% ethanol again and wash for 30 seconds, aspirate and discard the ethanol, centrifuge at low speed, aspirate and discard the remaining ethanol, leave at room temperature for 3 to 5 minutes, dry, add 30 μL of TE-low solution (pH 8.0), mix well, leave at room temperature for 5 minutes, place on a magnetic rack, leave for 3 to 5 minutes, completely clarify the solution, and take the supernatant.

[0051] (8) Sequencing: Sequencing was performed using an Illumina high-throughput sequencer, with a sequencing read of 2 × 150 bp.

[0052] (9) Data quality control: The amount of raw data of the sample must be 2G or more, the Q30 must be 75% or more, the average effective depth must be 500× or more, the coverage must be 98% or more, and the uniformity must be 90% or more.

[0053] (10) Data analysis: Amoydx Myeloid Leukemia Gene Mutation Detection Data Analysis System (ADXHS-AML) ) to analyze the detection data and output information on single base mutations, insertion / deletion mutations, and fusion mutations in the following genes: FLT3, TP53, RUNX1, CEBPA, DNMT3A, NPM1, TET2, WT1, NRAS, ASXL1, IDH2, KMT2A, KIT, KRAS, IDH1, PHF6, PTPN11, STAG2, NF1, U2AF1, BCOR, CBL, GATA2, SRSF2, NUP98, MLLT10, CREBBP, CBFB, ABL1, ETV6, NUP214, PML, ZRSR2, SF3B1, EZH2, CALR, RIT1, IKZF1, RB1, MYC, BRAF, CSF3R, GATA1, JAK2, JAK3, MPL, MYD88, PDGFRA, SETBP1, CTCF, DIS3, FBXW7, and MAX.

[0054] Conclusion: In this example (Myeloid Blood Cancer Panel), the mutations detected based on the liquid-phase capture technology (Master Panel) could be stably detected, and among the 25 mutations, the concordance rate of the corresponding SNVs was 100% (24 / 24), the detection concordance rate of the corresponding InDels was 100% (1 / 1), and the overall concordance rate was 100%. In addition, the correlation R of the mutation frequencies detected based on both HANDLE technology and liquid-phase capture technology (Myeloid Blood Cancer Panel and Master Panel) was 100%. 2 is greater than 0.92 (see Figure 3).

[0055] Example 3. Detection of mutations in 32 myeloid leukemia genes In this embodiment, probes for the detection of 32 drug targets and related genes according to expert consensus recommendations, including FLT3, TP53, RUNX1, CEBPA, DNMT3A, NPM1, TET2, WT1, NRAS, ASXL1, IDH2, KMT2A, KIT, KRAS, IDH1, PHF6, PTPN11, STAG2, NF1, U2AF1, BCOR, CBL, GATA2, SRSF2, NUP98, MLLT10, CREBBP, CBFB, ABL1, ETV6, NUP214, and PML, are selected to detect 15 clinical samples detected by liquid-phase capture technology, and a portion of the probe primer set is selected to examine the consistency of detecting the same sample.

[0056] In this example, the DNA probe set consists of sequences shown in SEQ ID NOs.0001-0008, SEQ ID NOs.0059-0082, SEQ ID NOs.0102-0131, SEQ ID NOs.0158-0172, SEQ ID NOs.0184-0280, SEQ ID NOs.0285-0293, SEQ ID NOs.0296-0302, SEQ ID NOs.0346-0351, SEQ ID NOs.0355-0459, SEQ ID NOs.0520-0640, SEQ ID NOs.0692-0836, SEQ ID NOs.0850-1001, and SEQ ID NOs.1026-1074, and all of the sequences of the DNA probe set are phosphorylated.

[0057] The RNA probe set consists of the sequences shown in SEQ ID NOs. 1075 to 1252 and SEQ ID NOs. 1264 to 1441, in which all six nucleotides from the 5' end of the sequences shown in SEQ ID NOs. 1075 to 1252 are modified with thiol, all of the sequences shown in SEQ ID NOs. 1264 to 1441 are phosphorylated, and all six nucleotides from the 3' end are modified with thiol.

[0058] The RNA reverse transcription primer set consists of the sequences shown in SEQ ID NOs. 1453 to 1630.

[0059] As shown in Figure 1, the specific process is as follows:

[0060] (1) Pre-denaturation: Aspirate 200 ng of RNA and 2 μL of MBCP-RT-Primers with a pipette, refill with water to 8.5 μL, and perform PCR at 65°C for 5 min. Then immediately place on ice.

[0061] (2) Reverse transcription: Add 1.25 μL of MBCP-RT Reaction Mix and 0.25 μL of MBCP-RT Reverse Transcriptase to the reaction mixture to make the total reaction mixture 10 μL. Perform PCR at 50°C for 50 minutes and at 98°C for 10 minutes, and store at 4°C.

[0062] (3) Hybridization: Add 50 ng of standard sample DNA to the reaction system, then add 2 μL of MBCP-Probe and 1 μL of MBCP-Hybridization Buffer, supplement with water to 20 μL, perform PCR at 98°C for 5 minutes and 60°C for 2 hours, and store at 4°C.

[0063] (4) Extension and ligation: 1 μL of MBCP-Extension Ligation Master Mix was added to the reaction system to make the total volume 21 μL. PCR was carried out at 60° C. for 10 minutes and then stored at 4° C.

[0064] (5) Enzyme cleavage: 0.5 μL of MBCP-Exonuclease A and 0.5 μL of MBCP-Exonuclease B are added to the reaction system so that the total volume becomes 22 μL. PCR is carried out at 37° C. for 30 minutes and at 95° C. for 10 minutes, and then stored at 4° C.

[0065] (6) PCR amplification: 1.5 μL of MBCP-N7 Primer, 1.5 μL of MBCP-S5 Primer, and 25 μL of MBCP-PCR Master Mix are added to the reaction system so that the total system becomes 50 μL. PCR is performed at 98°C for 1 minute (98°C, 20 seconds, 61°C, 30 minutes, 72°C, 20 minutes, 25 cycles), and then at 72°C for 5 minutes, and then stored at 4°C.

[0066] (7) Purification: Add 40 μL of AMPure XP beads (equilibrated at room temperature for 30 minutes) to 40 μL of the PCR product, mix well, leave at room temperature for 5 minutes, place on a magnetic rack, leave for 3 to 5 minutes, completely clarify the solution, discard the supernatant, add 200 μL of 80% ethanol and wash for 30 seconds, aspirate and discard the ethanol, add 200 μL of 80% ethanol again and wash for 30 seconds, aspirate and discard the ethanol, centrifuge at low speed, aspirate and discard the remaining ethanol, leave at room temperature for 3 to 5 minutes, dry, add 30 μL of TE-low solution (pH 8.0), mix well, leave at room temperature for 5 minutes, place on a magnetic rack, leave for 3 to 5 minutes, completely clarify the solution, and take the supernatant.

[0067] (8) Sequencing: Sequencing was performed using an Illumina high-throughput sequencer, with sequencing reads of 2 × 150 bp.

[0068] (9) Data quality control: The amount of raw data of the sample must be 1.5G or more, the Q30 must be 75% or more, the effective depth must be 500× or more, the coverage must be 98% or more, and the uniformity must be 90% or more.

[0069] (10) Data analysis: The detection data is analyzed using Xiamen AMOYDX Myeloid Leukemia Gene Mutation Detection Data Analysis System (ADXHS-AML-32), and information on single base mutations, insertion / deletion mutations, and fusion mutations of the genes FLT3, TP53, RUNX1, CEBPA, DNMT3A, NPM1, TET2, WT1, NRAS, ASXL1, IDH2, KMT2A, KIT, KRAS, IDH1, PHF6, PTPN11, STAG2, NF1, U2AF1, BCOR, CBL, GATA2, SRSF2, NUP98, MLLT10, CREBBP, CBFB, ABL1, ETV6, NUP214, and PML is output.

[0070] Conclusion: This example shows that the mutations detected based on liquid-phase capture technology can be stably detected, and among the 23 mutations, the corresponding SNV match rate is 100% (11 / 11), the corresponding InDel match rate is 100% (10 / 10), the corresponding Fusion match rate is 100% (2 / 2), and the total match rate is 100% (see Table 4). This shows that the 32-gene probe library set is also fully applicable to the detection of mutations according to detection needs. Table 4. Detection results of 32 gene probes for myeloid leukemia JPEG0007591097000042.jpg68170

[0071] Example 4. Mutation test of 10 myeloid leukemia genes To further illustrate the applicable situation of the present invention, this embodiment selects probes for detecting 10 drug targets and related genes according to expert consensus recommendations, including ABL1, KIT, FLT3, IDH1, IDH2, TP53, KMT2A, NUP98, NPM1, and NUP214, and this combination is applicable to pharmaceutical companies' trial clinical entry CTA or accompanying diagnostic CDx products. By detecting 15 clinical samples detected by liquid-phase capture technology, a part of the probe primer set is selected to examine the consistency of detecting the same sample.

[0072] In this embodiment, The DNA probe set is composed of sequences shown in SEQ ID NOs.0059 to 0066, SEQ ID NOs.0102 to 0131, SEQ ID NOs.0158 to 0172, SEQ ID NOs.0244 to 0280, SEQ ID NOs.0285 to 0293, SEQ ID NOs.0520 to 0625, and SEQ ID NOs.0821 to 0836, and all of the sequences of the DNA probe set are phosphorylated; The RNA probe sets were SEQ ID NO.1077, SEQ ID NO.1077, SEQ ID NO.1082 ~ 1168, SEQ ID NO.1170 ~ 1171, SEQ ID NO.1174, SEQ ID NO.1176, SEQ ID NO.1184 ~ 1186, SEQ ID NO.1188 ~ 1198, SEQ ID NO.1201, SEQ ID NO.1203 ~ 1221, SEQ ID NO.1234 ~ 1238, SEQ ID NO.1249 ~ 1252, SEQ ID NO.1266, SEQ ID NO.1271 ~ 1357, SEQ ID NO.1359 ~ 1360, SEQ ID NO.1363, SEQ ID NO.1365, SEQ ID NO.1373 ~ 1375, SEQ ID NO.1377 The sequences shown in SEQ ID NOs. 1387, 1390, 1392 to 1410, 1423 to 1427 and 1438 to 1441. In the sequences shown in SEQ ID NOs. 1077, 1082 to 1168, 1170 to 1171, 1174, 1176, 1184 to 1186, 1188 to 1198, 1201, 1203 to 1221, 1234 to 1238 and 1249 to 1252, all of the six nucleotides from the 5'-terminus are modified by thiolation. The sequences shown in SEQ ID NO.1266, SEQ ID NO.1271-1357, SEQ ID NO.1359-1360, SEQ ID NO.1363, SEQ ID NO.1365, SEQ ID NO.1373-1375, SEQ ID NO.1377-1387, SEQ ID NO.1390, SEQ ID NO.1392-1410, SEQ ID NO.1423-1427 and SEQ ID NO.1438-1441 are all phosphorylated and all six nucleotides from the 3' end are modified by thiolation.

[0073] The RNA reverse transcription primer set consists of the sequences shown in SEQ ID NO.1455, SEQ ID NO.1460-1546, SEQ ID NO.1548-1549, SEQ ID NO.1552, SEQ ID NO.1554, SEQ ID NO.1562-1564, SEQ ID NO.1566-1576, SEQ ID NO.1579, SEQ ID NO.1581-1599, SEQ ID NO.1612-1616 and SEQ ID NO.1627-1630.

[0074] As shown in Figure 1, the specific process is as follows:

[0075] (1) Pre-denaturation: Aspirate 200 ng of RNA and 2 μL of MBCP-RT-Primers with a pipette, refill with water to 8.5 μL, and perform PCR at 65°C for 5 min. Then immediately place on ice.

[0076] (2) Reverse transcription: 1.25 μL of MBCP-RT Reaction Mix and 0.25 μL of MBCP-RT Reverse Transcriptase were added to the reaction mixture to make the total reaction mixture 10 μL. PCR was performed at 50°C for 50 minutes and at 98°C for 10 minutes, and the mixture was stored at 4°C.

[0077] (3) Hybridization: Add 50 ng of standard sample DNA to the reaction system, then add 2 μL of MBCP-Probe and 1 μL of MBCP-Hybridization Buffer, supplement with water to 20 μL, perform PCR at 98°C for 5 minutes and 60°C for 2 minutes, and store at 4°C.

[0078] (4) Extension and ligation: Add 1 μL of MBCP-Extension Ligation Master Mix to the reaction system to make the total system 21 μL, perform PCR at 60° C. for 10 minutes, and store at 4° C.

[0079] (5) Enzyme cleavage: 0.5 μL of MBCP-Exonuclease A and 0.5 μL of MBCP-Exonuclease B were added to the above reaction system to make the total system 22 μL. PCR was carried out at 37° C. for 30 minutes and at 95° C. for 10 minutes, and then stored at 4° C.

[0080] (6) PCR amplification: 1.5 μL of MBCP-N7 Primer, 1.5 μL of MBCP-S5 Primer, and 25 μL of MBCP-PCR Master Mix were added to the reaction system so that the total system became 50 μL. PCR was performed at 98°C for 1 minute (98°C, 20 seconds, 61°C, 30 minutes, 72°C, 20 minutes, 25 cycles), and then at 72°C for 5 minutes, and then stored at 4°C.

[0081] (7) Purification: Add 40 μL of AMPure XP beads (equilibrated at room temperature for 30 minutes) to 40 μL of the PCR product, mix well, leave at room temperature for 5 minutes, place on a magnetic rack, leave for 3 to 5 minutes, completely clarify the solution, discard the supernatant, add 200 μL of 80% ethanol and wash for 30 seconds, aspirate and discard the ethanol, add 200 μL of 80% ethanol again and wash for 30 seconds, aspirate and discard the ethanol, centrifuge at low speed, aspirate and discard the remaining ethanol, leave at room temperature for 3 to 5 minutes, dry, add 30 μL of TE-low solution (pH 8.0), mix well, leave at room temperature for 5 minutes, place on a magnetic rack, leave for 3 to 5 minutes, completely clarify the solution, and take the supernatant.

[0082] (8) Sequencing: Sequencing was performed using an Illumina high-throughput sequencer, with sequencing reads of 2 × 150 bp.

[0083] (9) Data quality control: The amount of raw data of the sample must be 500M or more, the Q30 must be 75% or more, the average effective depth must be 500× or more, the coverage must be 98% or more, and the uniformity must be 90% or more.

[0084] (10) Data analysis: The detection data is analyzed using Xiamen AMOYDX Company's myeloid leukemia gene mutation detection data analysis system (ADXHS-AML-10), and information on single base mutations, insertion / deletion mutations, and fusion mutations in the genes ABL1, KIT, FLT3, IDH1, IDH2, TP53, KMT2A, NUP98, NPM1, and NUP214 is output.

[0085] Conclusion: This example shows that the mutations detected based on liquid-phase capture technology can be stably detected, and among the 15 mutations, the corresponding SNV concordance rate is 100% (5 / 5), the corresponding InDel concordance rate is 100% (8 / 8), the corresponding Fusion concordance rate is 100% (2 / 2), and the total concordance rate is 100% (see Table 5), and the 10-gene probe set can also be fully applied to the detection of leukemia mutations. Among them, the positive rate of FLT3-ITD was 26.6% (4 / 15), the positive rate of FLT3-TKD was 6.6% (1 / 15), the positive rate of NPM1 was 26.6% (4 / 15), the positive rate of IDH2 was 6.6% (1 / 15), the positive rate of KIT hotspot mutation D816V was 6.6% (1 / 15), and the positive rate of KMT2A (MLL) fusion was 13.3% (2 / 15), and the above mutations have clear guiding effect on drug development entry or clinical drugs. Table 5. Detection results of 10 gene probes for myeloid leukemia JPEG0007591097000043.jpg67170

[0086] The above description is merely a preferred embodiment of the present invention, and the scope of the present invention cannot be limited thereby; that is, any equivalent changes and modifications based on the claims and the contents of the specification of the present invention fall within the comprehensive scope of the present invention.

Claims

1. A probe primer set for detecting mutations in myeloid leukemia genes by high-throughput sequencing, comprising: The DNA probe set includes an RNA probe set and an RNA reverse transcription primer set, among which: The DNA probe set includes sequences shown in SEQ ID NO. 0059-0066, SEQ ID NO. 0102-0131, SEQ ID NO. 0158-0172, SEQ ID NO. 0244-0280, SEQ ID NO. 0285-0293, SEQ ID NO. 0520-0625 and SEQ ID NO. 0821-0836, and the sequences of the DNA probe set are all phosphorylated; The RNA probe sets are SEQ ID NO. 1077, SEQ ID NO. 1082-1168, SEQ ID NO. 1170-1171, SEQ ID NO. 1174, SEQ ID NO. 1176, SEQ ID NO. 1184-1186, SEQ ID NO. 1188-1198, SEQ ID NO. 1201, SEQ ID NO. 1203-1221, SEQ ID NO. 1234-1238, SEQ ID NO. 1249-1252, SEQ ID NO. 1266, SEQ ID NO. 1271-1357, SEQ ID NO. SEQ ID NO. 1359-1360, SEQ ID NO. 1363, SEQ ID NO. 1365, SEQ ID NO. 1373-1375, SEQ ID NO. 1377-1387, SEQ ID NO. 1390, SEQ ID NO. 1392-1410, SEQ ID NO. 1423-1427 and SEQ ID NO. 1438-1441, including the sequences set forth in SEQ ID NO. 1077, SEQ ID NO. 1082-1168, SEQ ID NO. 1170-1171, SEQ ID NO. 1174, SEQ ID NO. 1176, SEQ ID NO. In the sequences shown in SEQ ID NO. 1184-1186, SEQ ID NO. 1188-1198, SEQ ID NO. 1201, SEQ ID NO. 1203-1221, SEQ ID NO. 1234-1238 and SEQ ID NO. 1249-1252, all of the six nucleotides from the 5' end are modified with thiolation, and in the sequences shown in SEQ ID NO. 1266, SEQ ID NO. 1271-1357, SEQ ID NO. 1359-1360, SEQ ID NO. 1363, SEQ ID NO. 1365, SEQ ID NO. 1373-1375, SEQ ID NO. 1377-1387 and SEQ ID NO. The sequences shown in SEQ ID NOs. 1390, 1392-1410, 1423-1427 and 1438-1441 are all phosphorylated, and all six nucleotides from the 3' end are modified with thiol; A probe primer set for detecting a mutation in a myeloid leukemia gene by high throughput sequencing, characterized in that the RNA reverse transcription primer set comprises sequences shown in SEQ ID NO. 1455, SEQ ID NO. 1460-1546, SEQ ID NO. 1548-1549, SEQ ID NO. 1552, SEQ ID NO. 1554, SEQ ID NO. 1562-1564, SEQ ID NO. 1566-1576, SEQ ID NO. 1579, SEQ ID NO. 1581-1599, SEQ ID NO. 1612-1616 and SEQ ID NO. 1627-1630.

2. The DNA probe sets include SEQ ID NO. 0001-0008, SEQ ID NO. 0059-0082, SEQ ID NO. 0102-0131, SEQ ID NO. 0158-0172, SEQ ID NO. 0184-0280, SEQ ID NO. 0285-0293, SEQ ID NO. 0296-0302, SEQ ID NO. 0346-0351, SEQ ID NO. 0355-0459, SEQ ID NO. 0520-0640, SEQ ID NO. 0692-0836, SEQ ID NO. 0850-1001, and SEQ ID NO. 1026-1074, and all of the sequences of the DNA probe set are phosphorylated; The RNA probe set includes the sequences shown in SEQ ID NO. 1075-1252 and SEQ ID NO. 1264-1441, in which all six nucleotides from the 5' end of the sequence shown in SEQ ID NO. 1075-1252 are modified with thiol, all sequences shown in SEQ ID NO. 1264-1441 are phosphorylated, and all six nucleotides from the 3' end are modified with thiol, The probe primer set according to claim 1, wherein the RNA reverse transcription primer set comprises the sequences shown in SEQ ID NO. 1453-1630.

3. The DNA probe set comprises sequences shown in SEQ ID NO. 0001 to 1074, and all of the sequences shown in SEQ ID NO. 0001 to 1074 are phosphorylated; The RNA probe set includes the sequences shown in SEQ ID NO. 1075-1452, in which all six nucleotides from the 5' end are modified by thiol, the sequences shown in SEQ ID NO. 1264-1452 are all phosphorylated, and all six nucleotides from the 3' end are modified by thiol, The probe primer set according to claim 2, wherein the RNA reverse transcription primer set comprises the sequences shown in SEQ ID NO. 1453-1641.

4. The probe primer set according to claim 1 , comprising the DNA probe set, an RNA probe set and an RNA reverse transcription primer set.

5. The probe primer set according to claim 4, wherein the DNA probe set comprises a sequence represented by SEQ ID NO. 0001-1074.

6. The probe primer set according to claim 4, wherein the RNA probe set comprises the sequences shown in SEQ ID NO. 1075-1452.

7. The probe primer set according to claim 4, wherein the RNA reverse transcription primer set comprises the sequences shown in SEQ ID NO. 1453-1641.

8. The probe primer set according to claim 4, wherein the DNA probe set comprises a sequence shown in SEQ ID NO. 0001-1074, the RNA probe set comprises a sequence shown in SEQ ID NO. 1075-1452, and the RNA reverse transcription primer set comprises a sequence shown in SEQ ID NO. 1453-1641.

9. A kit for detecting a mutation in a myeloid leukemia gene by high-throughput sequencing, comprising the probe primer set according to any one of claims 1 to 8.

10. A method for using the probe primer set according to any one of claims 1 to 8 in the manufacture of a kit for detecting myeloid leukemia gene mutations by high-throughput sequencing.

Citation Information

Patent Citations

  • Detection test kit for gene mutation in acute myelogenous leukemia and application

    CN111154881A

  • Gene fusions and gene variants associated with cancer

    JP2016518123A

  • LSC and HSC signatures for predicting survival of patients having hematological cancer

    US20120237488A1

  • Marker for the detection and classification of leukemia from blood samples

    WO2012163941A2